Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Shalini Shenoy, MD
Professor of Pediatrics
Washington University School of Medicine
Medical Building Three
1020 N. Mason Road
St. Louis, Missouri, United States
Dr. Shenoy is currently working as professor of pediatrics in the division of Hematology/Oncology and General Pediatrics at Washington University School of Medicine. She also serves as Director, Pediatric Stem Cell Transplant Program at St. Louis Children’s Hospital.
She is the prinicipal investigator of national trials of unrelated donor transplantation for severe sickle cell disease termed as the SCURT Trial (Bone Marrow Transplant Clinical Trials Network 0601, NHLBI) and thalassemia termed as the URTH Trial (Thalassemia Clinical Research Network, NHLBI).
Dr. Shenoy’s research interests are focused on stem cell transplants for non-malignant disorders, reduced intensity transplants, and the immunologic mechanisms of graft rejection, graft versus host disease (GVHD), and immune reconstitution following stem cell transplantation (SCT).
Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation
The University of North Carolina Comprehensive Sickle Cell ProgramTo carry out basic, translational and cl...
John F. Tisdale, MDJohn F. Tisdale, MD graduated from the C...
Deepa G. Manwani, MDDr. Manwani completed her residency (199...
East Carolina University Comprehensive Sickle Cell CenterEast Carolina University Comprehensive S...
Coronavirus Preparedness for People With Chronic Diseaseshttps://www.youtube.com/watch?v=G_JC3vUT...
Today’s Faces of Sickle Cell Disease: Swee Lay Thein, MB, BS, FRCP, FRCPath, DScSwee Lay Thein was educated in both Mala...
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...